Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
A chemoprotectant is a medicine used to reduce damage to healthy tissue from certain anticancer treatments. It is given before, during, or after chemotherapy according to the drug and toxicity being prevented. Examples include amifostine, mesna, and dexrazoxane. A chemoprotectant supports cancer treatment but does not replace the anticancer medicine.
read more about chemoprotectant ...Chemoprotectants are used when a particular cancer treatment has a predictable risk of damaging a specific organ or tissue. Mesna helps protect the bladder from toxic metabolites produced by ifosfamide. Dexrazoxane can reduce selected anthracycline-related heart damage or treat anthracycline extravasation, depending on the product. Amifostine has approved uses involving selected cisplatin-related kidney toxicity and radiation-related dry mouth.
Different chemoprotectants use different protective mechanisms. Mesna binds and inactivates urotoxic compounds in the urinary tract. Dexrazoxane can reduce iron-dependent free-radical injury associated with anthracyclines and has additional enzyme-related effects. Amifostine is converted to an active thiol that can neutralize reactive molecules and protect normal tissues.
Administration depends on the protective agent and cancer regimen. Products can be given intravenously or by mouth using schedules tied closely to chemotherapy or radiation. Hydration, blood pressure, laboratory values, cardiac assessment, and other monitoring can be required. Incorrect timing or dosing can reduce protection or increase adverse effects.
Side effects differ by drug and can include nausea, vomiting, low blood pressure, allergic reactions, low blood-cell counts, or injection-related problems. A protective medicine can also have interactions or risks that affect the overall cancer regimen. Clinicians consider whether protection could alter anticancer effectiveness, although this concern depends on the agent and treatment setting. Patients should not add antioxidants or other products for chemoprotection without discussing them with the oncology team.
No. A chemotherapy drug attacks cancer cells, while a chemoprotectant is used to reduce selected treatment-related injury to healthy tissue.
Yes. Mesna protects the urinary tract from toxic metabolites associated with ifosfamide and selected related treatment settings.
No. A chemoprotectant reduces treatment-related toxicity, while a chemopreventive agent is intended to lower the risk of cancer developing or returning.
Some supplements can interact with cancer treatment or reduce its effectiveness. Patients should discuss every supplement with the oncology team before use.
Definition of Chemoprotective Agent. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/chemoprotective-agent. Date Accessed August 6, 2026.
Mesna Injection: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2a2a526f-636b-7920-4261-6c626f612a2a. Date Accessed August 6, 2026.
Dexrazoxane for Injection: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9c625fc-8852-4ed4-bcf2-63f46a706782. Date Accessed August 6, 2026.
ETHYOL (Amifostine) for Injection: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a17563f2-d231-4385-bc94-0217be78b89d. Date Accessed August 6, 2026.
Definition of Totect. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/totect. Date Accessed August 6, 2026.